CartiHeal

CartiHeal is a medical device company based in Israel and New Jersey, focused on developing and commercializing implants for treating cartilage and osteochondral defects in joints affected by trauma and osteoarthritis. Founded in 2009 in collaboration with Ben-Gurion University, CartiHeal aims to provide innovative solutions for cartilage lesions, particularly for patients with mild to moderate osteoarthritis. The company's main product, Agili-C, is a cell-free, off-the-shelf implant that has received CE marking in Europe and is commercially available in the U.S. for specific knee-joint surface lesions. Agili-C has been successfully implanted in over 500 patients during clinical trials, addressing a wide range of cartilage defects. CartiHeal has established a sales team to market Agili-C in leading U.S. hospitals, enhancing treatment options for the significant number of patients seeking cartilage repair. Recently, CartiHeal raised over $55 million in venture capital and was acquired by Smith & Nephew for up to $330 million, highlighting its strategic importance in the orthopedic medical device sector.

• Employees 18
• Founded 2009
• Annual Revenue $10000000
• Total Funding $60800000